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BSTRACT
 
Background
 
Beta radiation is effective in reducing
vascular neointimal proliferation in animals after inju-
ry caused by balloon angioplasty. However, the lowest
dose that can prevent restenosis after coronary angio-
plasty has yet to be determined.
 
Methods
 
After successful balloon angioplasty of a
previously untreated coronary stenosis, 181 patients
were randomly assigned to receive 9, 12, 15, or 18 Gy
of radiation delivered by a centered yttrium-90 source.
Adjunctive stenting was required in 28 percent of the
patients. The primary end point was the minimal lumi-
nal diameter six months after treatment, as a function
of the delivered dose of radiation.
 
Results
 
At the time of follow-up coronary angiogra-
phy, the mean minimal luminal diameter was 1.67 mm
in the 9-Gy group, 1.76 mm in the 12-Gy group, 1.83
mm in the 15-Gy group, and 1.97 mm in the 18-Gy
group (P=0.06 for the comparison of 9 Gy with 18 Gy),
resulting in restenosis rates of 29 percent, 21 percent,
16 percent, and 15 percent, respectively (P=0.14 for
the comparison of 9 Gy with 18 Gy). At that time, 86
percent of the patients had had no serious cardiac
events. In 130 patients treated with balloon angioplas-
ty without a stent, restenosis rates were 28 percent,
17 percent, 16 percent, and 4 percent, respectively (P=
0.02 for the comparison of 9 Gy with 18 Gy). Among
these patients, there was a dose-dependent enlarge-
ment of the lumen in 28 percent, 50 percent, 45 per-
cent, and 74 percent of patients, respectively (P<0.001
for the comparison of 9 Gy with 18 Gy). The rate of
repeated revascularization was 18 percent with 9 Gy
and 6 percent with 18 Gy (P=0.26).
 
Conclusions
 
Intracoronary beta-radiation therapy
produces a significant dose-dependent decrease in
the rate of restenosis after angioplasty. An 18-Gy dose
not only prevents the renarrowing of the lumen typ-
ically observed after successful balloon angioplasty,
but actually induces luminal enlargement. (N Engl
J Med 2001;344:243-9.)
 
Copyright © 2001 Massachusetts Medical Society.
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RTERIAL renarrowing after angioplasty,
or restenosis, occurs in 30 to 40 percent of
patients and results from neointimal pro-
liferation and constrictive remodeling of the
injured artery.
 
1
 
 A number of trials that took pharma-
cologic approaches to the prevention of restenosis have
evaluated more than 20 candidate drugs, but the re-
sults so far have been disappointing.
 
2
 
 Coronary stent-
ing has led to a 30 to 50 percent decrease in the rate
of restenosis, primarily by preventing the constrictive
remodeling of the artery, but at the cost of an increase
in neointimal proliferation.
 
3-5
 
 Thus, a new technique
for treatment that could prevent both neointimal hy-
perplasia and constrictive remodeling would be of
great clinical benefit.
Experimental evaluation of beta and gamma radi-
ation in animals has shown an inhibitory effect on
neointimal proliferation as well as on constrictive re-
modeling.
 
6-9
 
 Researchers applied a recently developed
technique of treatment with endovascular beta radi-
ation from an endoluminally centered, pure metallic
yttrium-90 source.
 
10-13
 
 In hypercholesterolemic rabbits,
the delivery of a 9-Gy dose of radiation 1 mm below
the surface of the tissue markedly inhibited neointimal
hyperplasia.
 
7
 
 However, in a study of safety and feasi-
bility, the same dose used in 15 patients did not have
a beneficial effect on restenosis.
 
14
 
 We hypothesized
A
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that higher doses of radiation were necessary, since
the arterial wall in humans is thicker than that in rab-
bits. Thus, the primary objective of the present study
was to determine the effect of 9, 12, 15, and 18 Gy of
beta radiation at a tissue depth of 1 mm on the rate
of restenosis after a first coronary angioplasty proce-
dure. Secondary objectives were to evaluate the safety
of the procedure and to assess the technical perform-
ance of the yttrium-90 system for intracoronary beta-
radiation therapy.
 
METHODS
 
Study Design and Objectives
 
The study was designed as a prospective, randomized, multicenter,
dose-finding trial. Between October 1997 and February 1999, 183
patients were enrolled in the trial at five European centers and ran-
domly assigned by computer, over the telephone, to receive 9 Gy,
12 Gy, 15 Gy, or 18 Gy of radiation. Patients more than 50 years
old who had angina pectoris or silent ischemia were enrolled if they
were suitable candidates for the dilation of a previously untreated
native coronary stenosis. For the enrollment criteria to be met, the
diameter of the vessel had to be between 2.5 and 4.0 mm, and the
stenosis had to be shorter than 15 mm. Patients also had to be el-
igible for angiographic and clinical follow-up at six months. Patients
were deemed ineligible if they had had a recent myocardial infarction
with abnormal base-line levels of cardiac enzymes, had a life expect-
ancy of less than six months, were pregnant, had had cancer within
the previous five years, had previously received mediastinal irradi-
ation, or were currently participating in another trial. Written in-
formed consent was obtained from all participating patients.
Irradiation was performed after the completion of the balloon an-
gioplasty. The physicians performing the angioplasty were discour-
aged from using multiple balloon inflations and balloon displace-
ments, so that the length of the vessel segment injured would be
limited. Beta irradiation was not performed if there was an urgent
need for stent implantation, if glycoprotein IIb/IIIa–receptor
blockers had been administered, or if there was abrupt vessel closure
that remained unresolved. Complementary stent implantation was
allowed in cases in which there were extensive dissections, sympto-
matic reductions in blood flow, or both. Initially, ticlopidine and
aspirin were given for two months after the procedure; starting in
November 1998, the duration of treatment with these drugs was
extended to seven months.
The primary end point of the study was the minimal luminal di-
ameter at six months within the vessel treated by balloon angioplas-
ty, as measured by quantitative coronary angiography, as a function
of the delivered dose of beta radiation. The secondary end points
were the incidences in the entire study population of the following
serious cardiac events: death, myocardial infarction, percutaneous
intervention in the target vessel (defined as any additional interven-
tion within the treated vessel), and coronary-artery bypass grafting.
Myocardial infarction was diagnosed when two of the following
occurred: chest discomfort lasting at least 30 minutes, the develop-
ment of abnormal new Q waves, and an increase in the level of cre-
atine kinase or MB isoenzymes to more than twice the upper lim-
it of normal.
 
Procedure for Radiation Therapy
 
The system used for intraarterial beta-radiation therapy has
been described previously
 
10-13
 
; it consists of the yttrium-90 beta-
ray–emitting source (half-life, 64 hours; maximal energy, 2.284
MeV), a centering balloon, and an automated delivery device. The
radioactive source consists of a 29-mm-long, flexible coil, secured
at the end of a 0.035-cm thrust wire between distal and proximal
6-mm-long, radiopaque tungsten markers, which allow precise lo-
calization of the source under fluoroscopy. The effective length of
the vessel segment being irradiated (the 90 percent isodose line)
is 24 mm. The centering balloon, consisting of four interconnect-
ed compartments, is designed to position the source wire central-
ly inside the coronary lumen, thereby contributing to a more ho-
mogeneous distribution of the dose of radiation along the vessel
wall. Three radiopaque markers are located between the balloon
compartments and allow the device to be positioned, with the use
of fluoroscopy, at the exact site of the previous angioplasty. The
centering balloon is inflated with 5 ml of carbon dioxide up to a
maximal pressure of 4 atm. As compared with the use of contrast
medium, the use of carbon dioxide permits faster inflation and de-
flation of the balloon and a shorter treatment time (because there
is less attenuation of the radiation).
 
11,12
 
The use of an automated delivery device ensured the safe storage
of the source, its easy insertion and withdrawal, its accurate posi-
tioning, and the instantaneous calculation and delivery of the dose.
At the end of each treatment, a printed report was automatically
generated. After the completion of balloon angioplasty, the center-
ing balloon, which had the same diameter as the angioplasty bal-
loon, was positioned so that it would cover fully the site dilated by
the angioplasty balloon. After the successful advancement and re-
trieval of a nonradioactive test wire, the yttrium-90 source was au-
tomatically advanced to the same site. This procedure was performed
by a team composed of a cardiologist, an oncologist, and a medical
physicist, who collaborated according to local practices and regu-
lations. All teams applied the measures normally used in the inter-
ventional suite for protection from radiation.
 
14
 
Angiographic Analysis
 
Coronary angiograms were obtained in multiple views after pa-
tients had received an intracoronary injection of nitrates. An inde-
pendent core laboratory (Cardialysis, Rotterdam, the Netherlands),
whose personnel were unaware of the dose of radiation associated
with each angiogram, analyzed the angiograms quantitatively using
edge-detection techniques.
 
15
 
 Coronary luminal diameter and degree
of stenosis (as a percentage of the diameter) were measured before
dilation, at the end of the procedure, and during follow-up angiog-
raphy six months later (or earlier if there were recurrent symptoms).
Restenosis was defined as the presence of stenosis of more than 50
percent of the luminal diameter. The loss in luminal diameter was
calculated as the difference between the luminal diameter measured
immediately after the procedure and that measured at six months.
The entire irradiated segment of the vessel (24 mm long) and the
edges of that segment (5 to 6 mm on each side of the segment)
were analyzed. The resulting segment (34 to 36 mm long) encom-
passed the initial site of stenosis, the 20-mm segment injured by
the angioplasty device, the 30-mm area affected by the centering
balloon, and the immediately adjacent proximal and distal segments
of the vessel (each 2 to 3 mm long). This method of analysis has
been used in previous trials of vascular brachytherapy.
 
15
 
Statistical Analysis
 
For a study with a power (1¡
 
b
 
) of 90 percent, a one-sided type
I error (
 
a
 
) of 0.05, and an expected minimal luminal diameter
at follow-up of 1.67 mm (that achieved in the Benestent II trial
 
5
 
among patients who underwent balloon angioplasty alone), with
a standard deviation of 27.5 percent, we calculated that we had to
enroll 34 patients in each group in order to detect a 20 percent
improvement in the minimal luminal diameter at six months (2.00
vs. 1.67 mm). In order to account for an expected 30 percent rate
of stent implantation, we increased the study population to 180
patients (45 in each of four groups).
For the comparison of binary variables, a Fisher’s exact test for
two groups was used, or the chi-square test was used when applica-
ble. For the comparison of continuous variables, two-tailed Stu-
dent’s t-tests were used. The data are expressed as means ±SE.
 
RESULTS
 
Patient Population
 
Of 183 patients who underwent randomization, 181
(mean age, 64±0.6 years; 74 percent male) received
Copyright © 2001 Massachusetts Medical Society. All rights reserved. 
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the prescribed doses of beta radiation: 45 received
9 Gy, 45 received 12 Gy, 46 received 15 Gy, and 45
received 18 Gy. Radiation therapy was not adminis-
tered in two cases (in one due to a technical failure,
and in one because the angioplasty was unsuccessful).
There were no significant differences among the dose
groups in terms of the demographic characteristics of
the patients or the characteristics of the lesions (Table
1). Balloon angioplasty alone was performed in 130
patients (72 percent). Stent implantation following
brachytherapy was required in 51 patients (in 47 per-
cent of these patients because of residual stenosis of
more than 50 percent of luminal diameter, and in the
remainder because of major dissection).
 
Angiographic Results
 
The mean degree of stenosis before the angioplasty
procedure, expressed as a percentage of the vessel di-
ameter, was 65±1.5, 64±1.6, 66±1.3, and 65±1.7 in
the 9-Gy, 12-Gy, 15-Gy, and 18-Gy groups, respective-
ly. There were no significant differences among the
groups in the mean degree of residual stenosis after
balloon angioplasty or in the postprocedural minimal
luminal diameter (Table 2). The mean duration of ra-
diation treatment was 1.81±0.10, 2.55±0.20, 3.01±
0.16, and 3.17±0.19 minutes, respectively, in the four
groups. Ten patients who were asymptomatic at six
months declined to undergo a second catheterization;
one patient died after having an acute myocardial in-
farction; and lung cancer was diagnosed in another
patient. The full complement of angiograms was thus
available for analysis in 169 patients; all three angio-
grams — preprocedural, postprocedural, and follow-
up — were suitable for quantitative analysis in 168 of
these patients.
The largest loss in minimal luminal diameter (from
the postprocedural result to follow-up) occurred with-
in the irradiated segment of the vessel (Fig. 1). Six
months after balloon angioplasty, a significant dose-
dependent benefit of beta radiation was evident in
the minimal luminal diameter (P=0.006 for the com-
parison of 9 Gy with 18 Gy); the mean diameter for
patients who had balloon angioplasty alone was 1.67±
0.09, 1.82±0.13, 1.80±0.11, and 2.10±0.12 mm,
 
*CABG denotes coronary-artery bypass grafting, PTCA percutaneous transluminal coronary an-
gioplasty, CAD coronary artery disease, LAD left anterior descending artery, RCA right coronary
artery, and LCX left circumflex coronary artery.
†The type of lesion was classified according to the American Heart Association–American College
of Cardiology classification, with A denoting a short focal lesion, and C the most complex type of
lesion.
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ABLE
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 C
 
HARACTERISTICS
 
 
 
OF
 
 
 
THE
 
 P
 
ATIENTS
 
.*
 
C
 
HARACTERISTIC
 
9 Gy
(N=45)
12 Gy
(N=45)
15 Gy
(N=46)
18 Gy
(N=45)
T
 
OTAL
 
(N=181)
 
mean ±SE
 
Age — yr 64±1.2 65±1.2 64±1.3 63±1.4 64±0.6
 
no. (%)
 
Male sex 32 (71) 30 (67) 35 (76) 36 (80) 133 (73)
Medical history
Previous infarction 15 (33) 20 (44) 18 (39) 16 (36) 69 (38)
Previous CABG 5 (11) 0 0 1 (2) 6 (3)
Previous PTCA 7 (16) 9 (20) 6 (13) 2 (4) 24 (13)
Family history of CAD 13 (29) 13 (29) 14 (30) 15 (33) 55 (30)
History of smoking 30 (67) 26 (58) 30 (65) 32 (71) 118 (65)
Current medical condition
Unstable angina 16 (36) 15 (33) 17 (37) 13 (29) 61 (34)
Diabetes mellitus 5 (11) 6 (13) 4 (9) 7 (16) 22 (12)
Hypertension 23 (51) 21 (47) 20 (43) 20 (44) 84 (46)
Hypercholesterolemia 26 (58) 27 (60) 27 (59) 24 (53) 104 (57)
Treated vessel
LAD 19 (42) 19 (42) 19 (41) 18 (40) 75 (41)
RCA 13 (29) 15 (33) 15 (33) 21 (47) 64 (35)
LCX 13 (29) 11 (24) 12 (26) 6 (13) 42 (23)
Lesion type†
A 4 (9) 7 (16) 6 (13) 8 (18) 25 (14)
B1 17 (38) 12 (27) 18 (39) 17 (38) 64 (35)
B2 24 (53) 26 (58) 22 (48) 20 (44) 92 (51)
C 0 0 0 0 0 
Single-vessel disease 36 (80) 34 (76) 36 (78) 32 (71) 138 (76)
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respectively (Table 2). The loss in luminal diameter
was 0.31±0.08 mm in the 9-Gy group, 0.12±0.09
mm in the 12-Gy group, and 0.09±0.10 mm in the
15-Gy group (Fig. 2). After irradiation at the 18-Gy
dose, the luminal diameter actually increased by 0.04±
0.10 mm (P=0.008 for the comparison of 9 Gy with
18 Gy). Luminal enlargement occurred in 28 percent,
50 percent, 45 percent, and 74 percent of the pa-
tients in the 9-Gy, 12-Gy, 15-Gy, and 18-Gy groups,
respectively (P<0.001 for the comparison of 9 Gy
with 18 Gy). On follow-up angiographic examination,
there was occlusion of the vessel in 4 of the 120 pa-
tients who had had balloon angioplasty alone (3.3 per-
cent) and in 7 of the 49 who had also required stents
 
*Plus–minus values are means ±SE. The P value for trend is 0.02 for the reference diameter at follow-up in all patients. The P value for trend is 0.07
for the minimal luminal diameter at follow-up and 0.08 for luminal loss in patients treated with balloon angioplasty alone. Follow-up data were available
and suitable for quantitative analysis in 168 patients.
†One of these patients had subacute thrombosis.
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 6 
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All patients (no.) 45 42 45 42 46 44 45 40
Reference diameter (mm) 2.95±0.07 2.83±0.07 3.02±0.09 3.01±0.09 2.99±0.09 2.98±0.09 3.11±0.07 3.21±0.08
Minimal luminal diameter (mm) 2.04±0.06 1.67±0.08 2.01±0.08 1.76±0.12 2.04±0.07 1.83±0.10 2.15±0.06 1.97±0.13
Stenosis (% of luminal diameter) 30.9±1.28 41.5±2.33 33.4±1.24 41.3±3.48 31.9±1.13 38.6±2.70 30.5±1.37 38.4±3.77
Luminal loss (mm) 0.37±0.07 0.25±0.10 0.21±0.09 0.18±0.12
Rate of restenosis (% of patients) 28.6 21.4 15.9 15.0
Vessel occlusion (no. of patients) 2† 4† 2† 4†
Patients treated with angioplasty alone (no.) 33 32 33 30 33 31 30 26
Reference diameter (mm) 2.93±0.09 2.81±0.09 2.94±0.08 2.96±0.09 2.89±0.11 2.90±0.11 3.08±0.09 3.09±0.09
Minimal luminal diameter (mm) 1.98±0.07 1.67±0.09 1.94±0.07 1.82±0.13 1.89±0.07 1.80±0.11 2.06±0.07 2.10±0.12
Stenosis (% of luminal diameter) 32.6±1.22 41.0±2.17 33.7±1.45 38.1±3.73 34.3±1.16 37.7±3.10 33.2±1.45 32.4±3.01
Luminal loss (mm) 0.31±0.08 0.12±0.09 0.09±0.10 ¡0.04±0.1
Rate of restenosis (% of patients) 28.1 16.7 16.1 3.9
Vessel occlusion (no. of patients) 0 2 1† 1
 
Figure 1.
 
 Loss in Minimal Luminal Diameter per Vessel Segment from Immediately after Angioplasty to Follow-up in
the 168 Patients for Whom Angiographic Follow-up Data Were Available at Six Months.
The mean (+SE) loss in minimal luminal diameter is shown for all patients in the four dose groups. The length of the
vessel segment analyzed was progressively increased from the obstructed segment to include the injured segment, the
irradiated segment plus the edges, and finally to the entire vessel (total). The loss decreased in a dose-dependent man-
ner, and the greatest loss occurred in the irradiated area. P=0.06 for the loss in the injured segment (9 Gy vs. 18 Gy).
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(14.3 percent). Of the patients with occlusion, four
(one treated with balloon angioplasty alone and three
who received stents) presented with acute symptoms
(at 7 days and at 10, 11, and 12 weeks after irradiation).
None of these patients were receiving long-term ticlo-
pidine treatment. As a consequence of the absence of
ticlopidine therapy, the rates of angiographic resteno-
sis in the patients who required stents were exceeding-
ly high: 30 percent, 33 percent, 15 percent, and 38
percent, respectively (22 percent, 20 percent, 8 per-
cent, and 20 percent, respectively, after the exclusion
of the patients with stent thrombosis).
 
Clinical Results
 
The incidence of serious cardiac events was within
the range of reported values and did not differ signif-
icantly among the dose groups (Table 3). The overall
incidence of myocardial infarction was 3.3 percent.
In addition, three patients had an isolated rise in the
creatine phosphokinase level. Repeated percutaneous
revascularization of the target vessel was required in
12 percent of the patients treated with balloon angio-
plasty alone and in 17.6 percent of the patients who
required stents.
 
DISCUSSION
 
This dose-finding study demonstrates a marked re-
duction in the rate of restenosis in nonstented arteries
after beta-radiation therapy at the 18-Gy level (at a tis-
sue depth of 1 mm). No device or pharmaceutical ap-
proach has yielded similarly low rates of restenosis
after balloon angioplasty alone. The lowest rate of re-
stenosis reported in the context of a randomized trial
was 16 percent at six months with the use of coronary
stents,
 
5
 
 which are currently implanted during more
than 60 percent of coronary interventions.
 
16
 
 With the
use of beta radiation, a restenosis rate of less than
5 percent was achieved in patients who had had good
 
Figure 2.
 
 Cumulative Frequency Distribution of the Loss in Minimal Luminal Diameter from Immedi-
ately after Angioplasty to Follow-up at Six Months in Patients Treated with Angioplasty and Irradiation
with 9, 12, 15, and 18 Gy of Beta Radiation.
As uniformly observed with any coronary intervention used in the past, the distribution curve at fol-
low-up after irradiation at the 9-Gy level is shifted to the right, indicating a progressive loss in the initial
luminal gain (P<0.001 for the comparison with 0 on the x axis [no change]). However, after irradiation
with 18 Gy, the distribution curve is shifted to the left (showing a negative loss), which is indicative of
luminal expansion between the postprocedural result and follow-up. The loss curves for the 12-Gy and
15-Gy groups show an intermediate response.
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*Only the most severe event in a given patient is shown. Periprocedural
creatine kinase values were elevated in three additional patients (2.5, 3.2,
and 3.6 times the upper limit of normal). CABG denotes coronary-artery
bypass grafting, and PTCA percutaneous transluminal coronary angioplasty.
†Death from cardiac causes after acute infarction occurred six months
after radiation and stent implantation in a 59-year-old patient who had had
recurrent angina three weeks earlier.
TABLE 3. INCIDENCE OF SERIOUS CARDIAC EVENTS AT 210 DAYS.*
EVENT
9 Gy
(N=45)
12 Gy
(N=45)
15 Gy
(N=46)
18 Gy
(N=45)
TOTAL
(N=181)
no. no. (%)
Death 0 0 0 1† 1 (0.6)
Myocardial infarction 1 2 0 2 5 (2.8)
Q-wave 0 1 0 1 2 (1.1)
Non–Q-wave 1 1 0 1 3 (1.7)
Target-vessel revas-
cularization
CABG
PTCA
0
6
1
3
0
5
0
5
1 (0.6)
19 (10.5)
None 38 39 41 37 155 (85.6)
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angiographic results after balloon angioplasty alone,
suggesting that beta-radiation therapy should be eval-
uated as a first-line adjunct to angioplasty. The effect
observed in our study results from the effect of irra-
diation on both remodeling and the formation of
neointima, as suggested by intravascular ultrasound
imaging.17,18
Several systems for endovascular irradiation with
sources of gamma or beta radiation have been devel-
oped. Gamma radiation was shown to decrease the
rates of restenosis after the percutaneous treatment of
restenotic lesions, but its effectiveness at the time of
the first angioplasty has not been evaluated.19-21 More-
over, the use of gamma radiation is less practical than
that of beta radiation in the environment of a cathe-
terization laboratory, because the medical staff must
be exposed to greater radiation and the treatment
times must be longer.
Results with other systems of beta radiation have
not been as encouraging as our results. The initial
analysis of the Beta Energy Restenosis Trial (BERT),
which used a noncentered strontium-90–yttrium-90
source, found a 15 percent rate of restenosis when the
angiographic analysis was limited to the stenotic seg-
ment.22 However, more recent reports using either
strontium-90–yttrium-90 or phosphorus-32 found
higher rates of restenosis (as high as 25 percent) when
a longer segment of the vessel was analyzed, as in our
study.23
Our data also indicate that caution should be ex-
ercised when combining radiation therapy with the
implantation of stents. Historically, the occurrence of
subacute stent thrombosis was reduced from 25 per-
cent to less than 2 percent when patients received
treatment with aspirin and ticlopidine for four weeks
after implantation.24-26 After irradiation, there was
abrupt thrombosis or late occlusion of vessels in 14.3
percent of patients with stents, a finding that is con-
sistent with other reports.27,28 By delaying endothe-
lialization after the implantation of a stent, radiation
therapy may extend the risk of stent thrombosis be-
yond four weeks. Further studies addressing the safety
of combining radiation therapy with stenting are nec-
essary; the long-term use of antiplatelet drugs will
presumably be required.
The use of radiation therapy for the treatment of
a nonmalignant disease may cause concern about sev-
eral potential problems. One is radiation-induced ar-
teriopathy, an arterial narrowing that occurs after ex-
ternal fractionated radiation treatment for malignant
diseases. This complication occurs after a mean of 16
years, and it occurs more frequently in younger pa-
tients in whom large volumes of tissue have been ir-
radiated.29 It is unknown whether this adverse effect
can occur several years after the irradiation of a small
volume of coronary artery. Another concern is that
remodeling of the vessel might ultimately result in the
formation of coronary aneurysms. Despite experimen-
tal30 and clinical31 evidence that radiation may induce
aneurysms, we did not observe this phenomenon. We
believe that the aneurysmal dilatations observed in ear-
lier studies were related to high-dose gamma radiation
of large volumes of tissue,32 but longer follow-up is
certainly warranted.
Another reason for concern is that radiation may
induce a soft-tissue sarcoma in the arterial wall or the
myocardium. Previous experience with radiation ther-
apy for breast cancer33 suggests that the maximal risk
of carcinogenesis during the 10-year period after in-
travascular radiation therapy is in the range of 1 case
per 1 million patients treated, given the small volume
of irradiated tissue. Radiation-induced cancers were
not found in large groups of patients who had received
radiation treatment for keloids or pterygia with fo-
cused doses of 12 and 18 Gy.34,35
Our principal findings have important implications
for the field of interventional cardiology. Current prac-
tice follows the “bigger is better” paradigm, which
holds that the bigger the luminal diameter achieved
by angioplasty, the better the long-term result.36 A
larger lumen can indeed be achieved safely and reli-
ably with the implantation of a stent. In this respect,
stents are superior to balloons, although they do not
inhibit the neointimal proliferation that causes reste-
nosis. Intracoronary beta radiation has the potential
to change this treatment paradigm, not only because
it reduces neointimal proliferation but also because of
its beneficial effect on the healing process in the arte-
rial wall. In a similar fashion to its effect on the healing
surgical wound,37,38 beta radiation decreases chronic
arterial constriction and induces luminal enlargement,
as we have shown. Further randomized trials should
therefore test the clinical efficacy of the combination
of beta-radiation therapy and balloon angioplasty, as
compared with the implantation of coronary stents,
in improving long-term, event-free survival after per-
cutaneous revascularization.
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APPENDIX
Other institutions and investigators that participated in the Dose-Find-
ing Study Group are as follows (the numbers of patients enrolled are given
in parentheses): University Hospital, Geneva (57) — I. Papirov, A. Sergey,
P. Debruyne, and J. Ramos de Olival; Cardiovascular Center, Onze-Lieve-
Vrouw Ziekenhuis, Aalst, Belgium (54) — G. Heyndrickx, L. Verbeke, and
J. De Jans; University Hospital, Essen, Germany (26) — M. Haude, D.
Flühs, U. Quast, A. Müller, K. Hidgeghty, and C. von Birgelen; University
Hospital, Kiel, Germany (22) — M. Thomas, G. Herrmann, R. Wilhelm,
and P. Kohl; King’s College Hospital, London (22) — N. Lewis; Study
Coordination (Boston Scientific) — T. Thaler; Critical Events Committee
— J. Dekkers; Angiographic Core Laboratory and Data Analysis — Y. Teu-
nissen, A. Spierings, C. van der Wiel, and G. Kloek.
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